Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis | Zendy

Eva Brunnemer | Zendy; Julia Wälscher | Zendy; Svenja Tenenbaum | Zendy; Julia Hausmanns | Zendy; Karen Schulze | Zendy; Marianne Seiter | Zendy; Claus Peter Heußel | Zendy; Arne Warth | Zendy; Felix J.F. Herth | Zendy; Michael Kreuter | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Author(s) -

Eva Brunnemer,

Julia Wälscher,

Svenja Tenenbaum,

Julia Hausmanns,

Karen Schulze,

Marianne Seiter,

Claus Peter Heußel,

Arne Warth,

Felix J.F. Herth,

Michael Kreuter

Publication year - 2018

Publication title -

respiration

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.264

H-Index - 81

eISSN - 1423-0356

pISSN - 0025-7931

DOI - 10.1159/000485933

Subject(s) - nintedanib , medicine , idiopathic pulmonary fibrosis , vital capacity , gastroenterology , pirfenidone , pulmonary function testing , placebo , adverse effect , interstitial lung disease , lung , diffusing capacity , lung function , pathology , alternative medicine

Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled trials by reducing the annual decline in forced vital capacity (FVC). However, real-world experience is limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research